Galderma Delivers 2024 Record Net Sales of 4.410 Billion USD, up 9.3% Year-on-Year at Constant Currency1, and Record Core EBITDA of 1.031 Billion USD, While Preparing to Accelerate Its Growth Trajectory Into 2025 and Beyond

This section is Partnership Content supplied The content in this section is supplied by Business Wire for the purposes of…

Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025

This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of distributing…